That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as ...
Spravato has been approved since 2019 for TRD, with its label extended the following year ... further evidence for the use of esketamine nasal spray in this difficult-to-treat population and ...